Aktienanalyse zu CEL-SCI Corp (CVM)CVMCEL-SCI Corp

CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

CVM is not a good buy right now due to significant financial losses and a declining stock price. The current price is $1.425, which is significantly below its 52-week high of $7.80, indicating a potential for further downside. Additionally, the company has reported a consistent negative EPS, with the latest at -$0.47, reflecting ongoing profitability challenges. The main risk is the company's high debt to equity ratio of 57.25%, which could hinder its financial flexibility and growth prospects.

1 analysts cover CVM: 0 rate it Buy, 1 Hold and 0 Sell.